TAS::75 0849::TAS CONTINUATION OF FOLLOW-UP OF DES-EXPOSED COHORTS

TAS::75 0849::TAS 继续对去暴露队列进行随访

• 批准号: 8179002
• 负责人: RAYMOND KAUFMAN
• 金额: $ 17.07万
• 依托单位: METHODIST HOSPITAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-30 至 2011-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8179002
• 关键词: Adenocarcinoma; Animal Model; Behavioral; Clear Cell; Cohort Studies; Collaborations; Collection; Daughter; Diethylstilbestrol; Disease; Estrogens; Europe; Exposure to; Female; Follow-Up Studies; Hospitals; Immune System and Related Disorders; Link; Mails; Malignant Neoplasms; Malignant neoplasm of prostate; Medical Records; Methodist Church; Mothers; Pathology Report; Pharmaceutical Preparations; Phase; Population Study; Pregnancy; Pregnant Women; Premature Birth; Preneoplastic Conditions; Prevention; Questionnaires; Reporting; Research; Research Institute; Risk; Son; Spontaneous abortion; Support Contracts; Vagina; Work; cancer risk; cohort; follow-up; high risk; in utero; male; malignant breast neoplasm; member; offspring; reproductive

Diethylstilbestrol (DES), a drug first synthesized in 1938, was administered to several million pregnant women in the U.S. and Europe for the prevention of spontaneous abortion and premature delivery. In 1971, Herbst reported a strong association between DES use in pregnancy and the occurrence of vaginal clear cell adenocarcinoma (CCA) in exposed female offspring. Animal models have demonstrated a range of DES effects on offspring exposed in utero, including reproductive dysfunction, immune system changes, behavioral and sexual abnormalities, and increases in various reproductive cancer in males and females. NCI, in collaboration with five field centers, reassembled previously studied cohorts of DES-exposed and unexposed mothers, daughters and sons, and identified subjects with documented exposure status who had not been studied previously, through familial links within the cohorts. Standardized baseline questionnaires were mailed to cohort members to ascertain the risk of cancer and other disorders. Pathology reports were collected for reported cancers and preneoplastic conditions. Three separate phases of follow-up have been conducted. The purpose of this study is to continue the follow-up, by means of mailed questionnaires and medical record collection, which was begun during the the first phase of the study. Concern has arisen that DES-exposed daughters may be at higher risk of breast cancer. Exposure to high levels of endogenous estrogen in utero has been hypothesized to increase the risk of breast cancer and DES is a potent estrogen. Cancer risk in the sons will also continue to be assessed, especially for increased risks of prostate cancer. since the offspring who were exposed to DES in utero are currently reaching their late forties, when cancer rates begin to rise, it is important to continue the follow-up of these cohorts to determine if there are long-term increases in cancer risk.

己烯雌酚 (DES) 是一种于 1938 年首次合成的药物，在美国和欧洲为数百万孕妇服用，用于预防自然流产和早产。 1971 年，Herbst 报告称，怀孕期间使用 DES 与暴露的雌性后代发生阴道透明细胞腺癌 (CCA) 之间存在密切关联。动物模型已证明 DES 对子宫内暴露的后代产生一系列影响，包括生殖功能障碍、免疫系统变化、行为和性异常，以及男性和女性各种生殖癌症的增加。 NCI 与五个现场中心合作，重新组合了先前研究的 DES 暴露和未暴露母亲、女儿和儿子的队列，并通过队列中的家庭联系识别出之前未曾研究过的记录有暴露状态的受试者。标准化基线调查问卷被邮寄给队列成员，以确定癌症和其他疾病的风险。收集所报告的癌症和癌前病症的病理学报告。已进行三个独立阶段的后续行动。本研究的目的是通过邮寄问卷和收集病历的方式继续进行在研究第一阶段开始的随访。人们担心接触 DES 的女儿患乳腺癌的风险可能更高。据推测，子宫内接触高水平的内源性雌激素会增加患乳腺癌的风险，而 DES 是一种有效的雌激素。儿子们的癌症风险也将继续进行评估，特别是前列腺癌风险的增加。由于在子宫内接触 DES 的后代目前已年近四十，癌症发病率开始上升，因此继续对这些队列进行随访以确定癌症风险是否长期增加非常重要。